SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

CYFENDUS

EBS·Emergent BioSolutions Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed (FDA approval July 20, 2023).
Why 4/10
CYFENDUS was FDA-approved in July 2023 and is already commercialized with no pending PDUFA, pivotal readout, or other hard binary catalyst scheduled in the next ~12 months. The drug's revenue is driven by periodic U.S. government contract modifications, which are not dated binary events. As an approved product without a pending regulatory decision, the impact score defaults to the 3-5 range.
Actionable Insight NEUTRAL

CYFENDUS is already approved and generating government contract revenue; watch for future BARDA contract modifications and any label expansion (e.g., pediatric or older adult populations) that could open new procurement. The Phase 2 booster study (NCT05997264) is ongoing but not a near-term binary. The stock's next major catalyst is company-wide, not drug-specific: the Q3 2026 earnings just reported today (Nov 2) showed anthrax MCM revenue up $23.7M year-over-year on CYFENDUS timing, but overall revenue fell 52% and guidance was lowered.

Price Chart

Loading chart...

Executive Summary

CYFENDUS (AV7909) is Emergent BioSolutions' FDA-approved two-dose anthrax vaccine for post-exposure prophylaxis, approved in July 2023. It offers faster protection than the older three-dose BioThrax vaccine and is sold primarily to the U.S. government for the Strategic National Stockpile under BARDA contracts. The drug is already commercialized with no pending regulatory binary catalyst. In Q3 2026, higher CYFENDUS sales drove a $23.7M year-over-year increase in anthrax medical countermeasure revenue, but the company overall faces headwinds: total revenue fell 52%, gross margins compressed, and full-year guidance was lowered. The stock trades near $5-6 with a mean analyst price target of $11.

How It Works

CYFENDUS is a vaccine that trains the immune system to recognize and neutralize the toxins produced by Bacillus anthracis, the bacterium that causes anthrax. It contains inactivated anthrax proteins plus an adjuvant (a booster ingredient) to strengthen the immune response. Unlike the older three-dose BioThrax vaccine, CYFENDUS requires only two doses, offering faster protection after someone has been exposed to anthrax spores. It is given together with antibiotics as part of post-exposure treatment.

Trial Status

CYFENDUS was approved by the FDA on July 20, 2023, based on a pivotal Phase 3 study evaluating immunogenicity and safety, a Phase 2 non-interference study with antibacterial drugs, and non-clinical efficacy studies. A Phase 2 booster study (NCT05997264) is ongoing to evaluate safety and immune response of different vaccination schedules and booster doses. An observational study (NCT07268612) is evaluating clinical benefit and safety in real-world post-exposure use.

The Two-Sided Case

▲ Bull Case5
CYFENDUS offers a key advantage over the older BioThrax: it is a two-dose regimen versus three-dose, providing faster protection. This makes it more attractive for strategic national stockpiling.
The U.S. government continues to invest: a $24M BARDA contract modification was awarded in September 2026 for additional CYFENDUS doses, and a broader $250M multi-product contract package included $30M for CYFENDUS.
Q3 2026 anthrax MCM product revenues increased $23.7M year-over-year, primarily attributable to higher U.S. government sales of CYFENDUS due to timing.
Institutional accumulation: multiple tracked managers added or doubled EBS positions in Q2 2026, including Millennium Management (doubled, +101%), Goldman Sachs (added, +28%), and Prudential (added, +80%).
Analyst consensus is bullish: 5 Buy/Strong Buy ratings vs 1 Hold and 1 Sell, with a mean price target of $11 (implying ~61% upside from the $6.81 close before today's earnings).
▼ Bear Case4
CYFENDUS competes with Emergent's own older product BioThrax, which may cannibalize sales. In Q4 2025, CYFENDUS product sales actually decreased, partially offsetting growth in BioThrax and ANTHRASIL sales.
The entire anthrax vaccine market is driven almost entirely by U.S. government biodefense procurement, not patient demand, making revenue lumpy and dependent on annual contract exercises and political priorities.
Emergent BioSolutions faces broader financial challenges: Q3 2026 total revenue fell 52% to $110M, GAAP gross margin collapsed to 14%, and the company lowered full-year 2026 guidance. The stock trades near multi-year lows around $5-6.
Insider selling: Director Donald DeGolyer sold $126K worth of shares on Oct 7, 2026, and SVP Paul Williams sold $19.6K on Oct 1, 2026, both under 10b5-1 plans.

Upcoming Catalysts

  • Future BARDA contract modifications or renewals for CYFENDUS supply to the Strategic National Stockpile
  • Phase 2 booster study (NCT05997264) results on 6- and 12-month booster schedules
  • Potential label expansion to pediatric or older adult populations
  • Observational study (NCT07268612) real-world safety and efficacy data

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Emergent BioSolutions Inc. 8-K EBS ·Originating report

Sources · 9

Hover a chip for the title
1 fda.gov2 investors.emergentbiosolutions.com3 investors.emergentbiosolutions.com4 biospace.com5 content.govdelivery.com6 citybiz.co7 emergentbiosolutions.com8 globalbiodefense.com9 tradingkey.com